
ASX Announcement and Media Release

4 August 2005

SciGen Limited

Appointment of Chief Executive Officer

The Board of SciGen Limited ("SciGen") is pleased to announce the reappointment of the Company Executive Vice Chairman and Founder Mr. Saul Mashaal Phmb, MBA to the position of CEO.

In addition to his CEO responsibility Mr. Mashaal will continue to be responsible for the Business Development, In and Out-licensing, R & D and Manufacturing.

Mr. Mashaal has more than 30 years experience in the Pharmaceutical Industry first with Syntex Corporation in Product Management and later with 3M Health & Sciences Sector where he had a long and successful career in various disciplines including Clinical Research and International Business Development. In 1988 he founded SciTech Genetics in Singapore and in 1999 all of SciTech Genetics product portfolio of BioPharmaceutical products were transferred to what is now SciGen. Soon after SciGen attracted major investors such as Sonic Healthcare and more recently Bioton. He remained the CEO of SciGen until September 2001 when the Executive Management was transferred to Australia.

About SciGen

SciGen Ltd is a biopharmaceutical company essentially involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland and the Netherlands.

=====ENDS=====

Media enquiries

Saul Mashaal
Executive Vice Chairman, Founder and Chief Executive Officer
Telephone: +61 2 9234 1700/ +65 6779 6638
Web: www.scigen.com.au